COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Pheton Holdings Ltd Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency23/10/2025
-   
  Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 202523/10/2025
-   
  AVAVA Earns New FDA Clearance for the Treatment of Wrinkles23/10/2025
-   
  Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting23/10/2025
-   
  Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 202523/10/2025
-   
  Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report23/10/2025
-   
  Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease23/10/2025
-   
  New Clinical Data Confirms Yomi® Robotic System Enhances Efficiency in Dental Implant Surgery23/10/2025
-   
  Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 202523/10/2025
-   
  Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules23/10/2025
-   
  Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 202523/10/2025
-   
  Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors23/10/2025
-   
  Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 202523/10/2025
-   
  SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer23/10/2025
-   
  Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts23/10/2025
-   
  Instinct Science and Cornell University Hospital for Animals Modernize Veterinary Care with Instinct Treatment Plan23/10/2025
-   
  Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.23/10/2025
-   
  Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.23/10/2025
-   
  Avec Med4Cure, EUROAPI accélère l’innovation pharmaceutique au service de la souveraineté sanitaire23/10/2025
Pages